First Patient Dosed of Phase 2 Clinical Trial of Serplulimab in Combination with Innovative Anti-LAG-3 mAb for the Treatment of Metastatic Colorectal Cancer Patients

Shanghai, China, June 15th, 2023 - Shanghai Henlius Biotech, Inc. (2696.HK) announced that the first patient has been dosed in a phase 2 clinical trial (NCT05584137) of HANSIZHUANG (serplulimab injection), an innovative anti-PD-1 monoclonal antibody (mAb) independently developed by the company, in combination with HLX26, an innovative anti-LAG-3 mAb for the trea

Fosun Ranks 5th on China ESG (Corporate Social Responsibility) Release’s List of China’s Top 100 ESG Listed Companies

On the afternoon of 13 June 2023, the Financial Program Center of China Media Group (CMG), together with the State-owned Assets Supervision and Administration Commission of the State Council (SASAC), the All-China Federation of Industry and Commerce (ACFIC), the Institute of Economics of the Chinese Academy of Social Sciences (CASS), the China Enterprise R

Henlius Shines for Five Consecutive Years at BIO International Convention

Wolves announce Partnership with Shede Spirits

The new partnership will see Shede’s Tuopai brand become the club’s Official Baijiu Partner for the 2023/24 season.Tuopai is one of the best known and well renowned liquor brands in China.With sales of over five billion bottles in the country, Tuopai has left a profound impression on generations of Chinese people, and the partnership with Wolves will further grow the b

Investor Open Day: Fosun Implements Business Streamlining and Resilience Building Strategy, Focusing on Core Businesses to Bring New Vitality